- Home
- MTVA vs BRTX Comparison
MTVA vs BRTX Comparison
Compare MTVA & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTVA
- BRTX
- Stock Information
- Founded
- MTVA 2014
- BRTX 1997
- Country
- MTVA United States
- BRTX United States
- Employees
- MTVA N/A
- BRTX N/A
- Industry
- MTVA
- BRTX Managed Health Care
- Sector
- MTVA
- BRTX Health Care
- Exchange
- MTVA NYSE
- BRTX Nasdaq
- Market Cap
- MTVA 16.8M
- BRTX 15.9M
- IPO Year
- MTVA N/A
- BRTX N/A
- Fundamental
- Price
- MTVA $1.60
- BRTX $1.80
- Analyst Decision
- MTVA Strong Buy
- BRTX Strong Buy
- Analyst Count
- MTVA 1
- BRTX 1
- Target Price
- MTVA $12.00
- BRTX $18.00
- AVG Volume (30 Days)
- MTVA 23.0K
- BRTX 812.7K
- Earning Date
- MTVA 03-27-2025
- BRTX 03-28-2025
- Dividend Yield
- MTVA N/A
- BRTX N/A
- EPS Growth
- MTVA N/A
- BRTX N/A
- EPS
- MTVA N/A
- BRTX N/A
- Revenue
- MTVA N/A
- BRTX $377,000.00
- Revenue This Year
- MTVA N/A
- BRTX $482.76
- Revenue Next Year
- MTVA N/A
- BRTX $212.24
- P/E Ratio
- MTVA N/A
- BRTX N/A
- Revenue Growth
- MTVA N/A
- BRTX 189.55
- 52 Week Low
- MTVA $1.51
- BRTX $1.03
- 52 Week High
- MTVA $6.75
- BRTX $2.55
- Technical
- Relative Strength Index (RSI)
- MTVA N/A
- BRTX 37.55
- Support Level
- MTVA N/A
- BRTX $2.26
- Resistance Level
- MTVA N/A
- BRTX $2.38
- Average True Range (ATR)
- MTVA 0.00
- BRTX 0.22
- MACD
- MTVA 0.00
- BRTX -0.09
- Stochastic Oscillator
- MTVA 0.00
- BRTX 7.98
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.